Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654716 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03654716 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT03654716, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: * ALRN-6924 * Cytarabine (for patients with leukemia only)
Interventions
- DRUG Cytarabine
- DRUG ALRN-6924
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2023-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654716
The ClinicalTrials.gov registry entry for NCT03654716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT03654716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03654716 about?
NCT03654716 is a clinical study titled "Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer". This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia. The drugs involved in this study are: * ALRN-6924 * Cytarabine (for patients with leukemia only)
What is the current status of trial NCT03654716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-11-01. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT03654716?
The interventions under investigation include: Cytarabine (DRUG), ALRN-6924 (DRUG).
Who is sponsoring clinical trial NCT03654716?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.